Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients.
Temporal trends from 1986 to 2008 in overall survival of small cell lung cancer patients.
复制标题
DOI：
10.1016/j.lungcan.2014.07.014
复制
发表时间：
2014-10
期刊：
影响因子：
--
通讯作者：
Chiappori AA
中科院分区：
文献类型：
--
作者：
Schabath MB;Nguyen A;Wilson P;Sommerer KR;Thompson ZJ;Chiappori AA
对患者生存时间趋势的评估对于确定患者结局的进展并揭示必须取得进展的地方非常重要。这项研究评估了小细胞肺癌（SCLC）患者22年来人口统计学、临床特征和总生存期的时间变化。该分析包括1，032名SCLC患者，从H. Lee Moffitt癌症中心和研究所：1986年至1999年（编号= 410）和2000年至2008年（编号= 622）。Kaplan-Meier生存曲线和对数秩统计用于评估两个时间段的生存率，多变量考克斯比例风险模型用于生成风险比（HR）和95%置信区间（CI）。总的5年生存率从1986年至1999年的8.3%显著增加到11.0%（P < 0.001）2000年至2008年期间，中位生存时间从11.3个月（95% CI 10.5-12.7）至15.2个月（95% CI 13.6-16.6）我们还观察到两个时间段内阶段特异性中位生存时间和生存率显著增加。对整个队列的多变量考克斯比例风险模型显示，1986年至1999年诊断的患者死亡风险显著增加（HR = 1.29; 95% CI 1.11 - 1.49），诊断年龄在60 - 69岁之间的患者（HR = 1.33; 95% CI 1.04 - 1.49）和70岁以上（HR = 1.63; 95% CI 1.26 - 2.11），男性（HR = 1.33; 95% CI 1.16 - 1.53），未接受第一疗程治疗的患者（HR = 2.17; 95% CI - 3.00）和广泛期SCLC（HR = 2.79; 95%CI 2.35 - 3.30）该分析表明，从1986年至2008年在Moffitt癌症中心治疗的SCLC患者的总体和分期特异性中位生存时间和生存率显著改善。
An assessment of temporal trends in patient survival is important to determine the progress towards patient outcomes and to reveal where advancements must be made. This study assessed temporal changes spanning 22 years in demographics, clinical characteristics, and overall survival of small cell lung cancer (SCLC) patients. This analysis included 1,032 SCLC patients spanning two time-periods from the H. Lee Moffitt Cancer Center and Research Institute: 1986 to 1999 (No. = 410) and 2000 to 2008 (No. = 622). Kaplan-Meier survival curves and log-rank statistics were used to assess survival rates across the two time-periods and multivariable Cox proportional hazards models were used to generate hazard ratios (HRs) and 95% confidence intervals (CIs). The overall 5-year survival rate significantly increased from 8.3% for the 1986 to 1999 time-period to 11.0% (P < 0.001) for the 2000 to 2008 time-period, and the median survival time increased from 11.3 months (95% CI 10.5–12.7) to 15.2 months (95% CI 13.6–16.6) We also observed significant increases in stage-specific median survival times and survival rates across the two time-periods. A multivariable Cox proportional hazards model for the entire cohort revealed significant increased risk of death for patients diagnosed in 1986 to 1999 (HR = 1.29; 95% CI 1.11 – 1.49), patients diagnosed between 60 and 69 years of age (HR = 1.33; 95% CI 1.04 – 1.49) and over 70 years of age (HR = 1.63; 95% CI 1.26 – 2.11), men (HR = 1.33; 95% CI 1.16 – 1.53), patients with no first course treatment (HR = 2.17; 95% CI – 3.00) and extensive stage SCLC (HR = 2.79; 95% CI 2.35 – 3.30) This analysis demonstrated significant improvements in overall and stage-specific median survival times and survival rates of SCLC patients treated at the Moffitt Cancer Center from 1986 to 2008.